Is ARRY a buy?

Out of 9 analysts, 2 (22.22%) are recommending ARRY as a Strong Buy, 1 (11.11%) are recommending ARRY as a Buy, 5 (55.56%) are recommending ARRY as a Hold, 0 (0%) are recommending ARRY as a Sell, and 1 (11.11%) are recommending ARRY as a Strong Sell. What is ARRY’s earnings growth forecast for 2021-2023?

Will Array Technologies stock go up?

Will Array Technologies stock price grow / rise / go up? Yes. The ARRY stock price can go up from 19.280 USD to 24

Is Array Technologies a buy?

Investor Takeaway. Array Technologies has fallen hard since the earnings release, as management pulled guidance due to unforeseen rises in steel and shipping costs. Array is currently a Buy for investors who have a well-diversified portfolio and can accept near-term uncertainty.

Why is ARRY stock going down?

Disruption from the pandemic impacted the company’s results. Array CEO Jim Fusaro addressed why earnings were lower than Array’s internal expectations, noting “higher than expected logistics costs.” But uncertainty looking ahead is what caused investors to sell in droves.

Is Paya a good stock to buy?

Paya has received a consensus rating of Buy.

Is Arry a good stock?

Array Biopharma Inc (NASDAQ:ARRY) is not the most popular stock in this group but hedge fund interest is still above average. Our calculations showed that top 5 most popular stocks among hedge funds returned 95.8% in 2019 and 2020, and outperformed the S&P 500 ETF (SPY) by 40 percentage points.

What does Array BioPharma do?

Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Who owns array technologies?

Ron P. Corio
Key Executives

Name	Title	Exercised
Mr. James M. Fusaro	CEO & Director	N/A
Mr. Ron P. Corio	Founder & Director	N/A
Mr. Jeffrey P. Krantz	Chief Commercial Officer	N/A
Mr. Nipul A. Patel	Chief Financial Officer	N/A

Who bought Array Biopharma?

Pfizer
In June 2019, Pfizer acquired the company for approximately $11 billion.

How many employees does array technologies have?

230
Array Technologies, Inc. is located in Albuquerque, NM, United States and is part of the Hardware Manufacturing Industry. Array Technologies, Inc. has 230 total employees across all of its locations and generates $872.66 million in sales (USD).

What kind of stock does array technologies have?

What Will the Stock Market Do Today? 3 Big Stories to Watch. Array Technologies, Inc. manufactures ground-mounting systems used in solar energy projects.

Who is the founder of array Technologies Inc?

The company’s products include DuraTrack and SmarTrack. Array Technologies was founded by Ronald P. Corio in 1989 and is headquartered in Albuquerque, NM.

Is there a class action lawsuit against array technologies?

Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

Who is the Rosen law firm array technologies?

NEW YORK, NY / ACCESSWIRE / June 12, 2021 / WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Array Technologies, Inc.

What Will the Stock Market Do Today? 3 Big Stories to Watch. Array Technologies, Inc. manufactures ground-mounting systems used in solar energy projects.

What kind of company is Array BioPharma?

Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases.

The company’s products include DuraTrack and SmarTrack. Array Technologies was founded by Ronald P. Corio in 1989 and is headquartered in Albuquerque, NM.